A named patient program of Emcitate for MCT8 deficiency
Latest Information Update: 12 Oct 2023
At a glance
- Drugs Tiratricol (Primary)
- Indications Allan-Herndon-Dudley syndrome
- Focus Expanded access; Therapeutic Use
- Sponsors Egetis Therapeutics
- 09 Oct 2023 According to an Egetis Therapeutics media release, more than 180 patients in over 25 countries, are currently being treated with Emcitate as part of the Companys Expanded Access/ Compassionate Use programs.
- 26 Apr 2021 New trial record
- 22 Apr 2021 According to an Egetis Therapeutics media release, Emcitate is supplied on a named patient basis, following individual regulatory approval from the national regulatory agency.